Nuvectis Pharma (NVCT) to Release Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) is expected to be posting its Q4 2024 quarterly earnings results before the market opens on Tuesday, March 4th. Analysts expect Nuvectis Pharma to post earnings of ($0.28) per share for the quarter.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvectis Pharma Trading Down 0.3 %

NVCT traded down $0.02 during mid-day trading on Friday, hitting $6.69. 28,728 shares of the stock were exchanged, compared to its average volume of 114,701. The firm's fifty day moving average is $6.26 and its two-hundred day moving average is $6.41. Nuvectis Pharma has a 1-year low of $4.44 and a 1-year high of $12.10. The company has a market cap of $129.26 million, a PE ratio of -5.77 and a beta of 0.22.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their target price on shares of Nuvectis Pharma from $21.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday.

Remove Ads

Insider Buying and Selling at Nuvectis Pharma

In other news, major shareholder Marlio Charles Mosseri acquired 240,000 shares of Nuvectis Pharma stock in a transaction dated Friday, February 7th. The shares were acquired at an average cost of $5.00 per share, for a total transaction of $1,200,000.00. Following the acquisition, the insider now owns 2,884,121 shares of the company's stock, valued at $14,420,605. This trade represents a 9.08 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have purchased 261,500 shares of company stock valued at $1,300,825 in the last quarter. Corporate insiders own 35.78% of the company's stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.